Cost-effectiveness of novel treatment of hepatitis C virus in Lebanese patients

LAUR Repository

Show simple item record

dc.contributor.author Nasser, Soumana C.
dc.contributor.author Mansour, Hanine
dc.contributor.author Abi Nader, Tatiana
dc.contributor.author Metni, Mirna
dc.date.accessioned 2019-11-07T10:02:49Z
dc.date.available 2019-11-07T10:02:49Z
dc.date.copyright 2018 en_US
dc.date.issued 2019-11-07
dc.identifier.issn 2210-7711 en_US
dc.identifier.uri http://hdl.handle.net/10725/11501
dc.description.abstract Background Limited data is available on Hepatitis C disease prevalence, treatment initiation and its cost-effectiveness in Lebanon and the whole Middle East. Objective The aim of the study is to assess whether initiation of novel Direct Acting Antiviral agents (DAAs) at early stage of hepatitis C is cost-effective in Lebanese patients. Setting Lebanon. Methods This modeling study was conducted from the perspective of Lebanese third party payers, where existing practice is based on international guidelines for the diagnosis and treatment of diseases. The model assessed cost-effectiveness of early versus delayed DAAs treatment in a standard patient upon HCV diagnosis. Medical costs were valued using in-house database. Main outcome measures Incremental Cost-Effectiveness Ratio (ICER) per QALY and per life-year extended. Results Treatment at early HCV disease stage has led to an ICER of 587 euro per QALY gained throughout the course of the disease. Outcomes of early treatment with DAAs upon HCV diagnosis led to an incremental cost of 27,268 euro per QALY gained at first year of treatment, and of 1527 euro per additional life-year extended. Sensitivity analysis showed that a 25% decrease in the cost of dual drug option resulted in a decrease of incremental cost to 16,982 euro per QALY gained at first year of treatment with DAAs upon early HCV diagnosis. Conclusion Decision makers are encouraged to reinforce the need to screen for HCV and initiate novel treatment at early disease stage in the Lebanese healthcare system. en_US
dc.language.iso en en_US
dc.title Cost-effectiveness of novel treatment of hepatitis C virus in Lebanese patients en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOP en_US
dc.author.idnumber 199231640 en_US
dc.author.idnumber 201205628 en_US
dc.author.department Pharmacy Practice en_US
dc.description.embargo N/A en_US
dc.relation.journal International Journal of Clinical Pharmacy en_US
dc.journal.volume 40 en_US
dc.journal.issue 3 en_US
dc.article.pages 693-699 en_US
dc.keywords Cost-effectiveness en_US
dc.keywords Delayed treatment en_US
dc.keywords Direct acting anti-viral agents en_US
dc.keywords Early treatment en_US
dc.keywords Hepatitis C virus en_US
dc.keywords Lebanon en_US
dc.keywords QALYs en_US
dc.identifier.doi https://doi.org/10.1007/s11096-018-0628-6 en_US
dc.identifier.ctation Nasser, S. C., Mansour, H., Abi Nader, T., & Metni, M. (2018). Cost-effectiveness of novel treatment of hepatitis C virus in Lebanese patients. International Journal of Clinical Pharmacy, 40(3), 693-699. en_US
dc.author.email soumana.nasser@lau.edu.lb en_US
dc.author.email hanine.mansour@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://link.springer.com/article/10.1007/s11096-018-0628-6 en_US
dc.orcid.id https://orcid.org/0000-0003-4202-7116 en_US
dc.orcid.id https://orcid.org/0000-0001-6383-0288 en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account